Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II study assessing the activity of bevacizumab combined with atezolizumab in
metastatic urothelial carcinoma patients who are ineligible for cisplatin-based therapy.